Colossal Biosciences reported in talks to raise at a $20bn-$30bn valuation
Axios reported that Colossal was in discussions for a new funding round valuing the de-extinction company at $20bn to $30bn, against the $10.2bn it achieved in its $200m Series C and the $10.3bn carried after a $120m dodo-specific raise in September 2025. Total capital raised to date is roughly $555m; no round has been confirmed as closed.